National Desk, Delhi Magazine: A good news has emerged for India battling the second wave of Corona virus. The Controller General of Pharmaceuticals of India (DCGI) has approved the emergency use of anti-Covid drug developed by DRDO. In the initial trial of this drug, it has been found that this also improves the oxygen level of the patient.
The Ministry reported that medical testing revealed that 2-deoxy-D-glucose (2-DG) drugs help the hospitalized patients recover faster, as well as reduce the dependence of excess oxygen. The drug has been developed by the Defense Research and Development Organization (DRDO), the prestigious laboratory of the Institute of Nuclear Medicine and Allied Sciences (INMAS) in association with Dr. Reddy Laboratory of Hyderabad.
The ministry said that the 2-DG drug comes in a packet in the form of powder, it has to be dissolved in water and drink. The ministry said in a statement, “On May 1, DCGI has given this claim to Covid-19’s medium and Approved the use of emergency as a supportive method to treat patients with severe symptoms. It can be prepared in large quantities in the country due to its conformity with normal molecules and glucose.
The ministry said, “DRDO’s 2-DG drug accumulates in the virus-infected cell and inhibits the growth of the virus. Working selectively on a virus-infected cell is what makes this drug special.
2nd Phase Trial of 2-DG
In May 2020, DGCI started a second phase clinical trial of 2-DG on corona patients. The drug 2-DG was found safe in an October 2020 trial. This helped corona patients recover faster.
3rd Trial of 2-DG
From December 2020 to March 2021, a third phase trial was conducted on 220 corona patients. The trial was conducted in 27 hospitals in Delhi, UP, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. During the third day, oxygen dependence of patients decreased from 42% to 31% during the trial. The special thing is that patients over 65 years of age also showed positive response to the drug.
Patients were cured two and a half days ago
In April 2020, during the first wave of the Covid-19 pandemic, INMAS-DRDO scientists tested 2-DG in the lab with the help of Cellular and Molecular Biology (CCMB) of Hyderabad. Compared to the Standard of Care (SoC) standard, patients taking the drug were cured two and a half days earlier than other patients.